肾旁腹主动脉瘤腔内修复术围手术期死亡率低于开放手术的系统综述与荟萃分析
该系统综述与荟萃分析检索2000年至2018年比较肾旁腹主动脉瘤腔内修复与开放手术的研究,最终纳入14项研究共5121例患者(腔内1506例、开放3615例)。结果显示腔内修复与30天死亡率、急性肾衰竭和住院时间降低相关,但脊髓缺血发生率升高。
要点
- 腔内修复与30天死亡率显著降低相关(OR 0.50,95%CI 0.34-0.74,P<.001)。
- 腔内修复组急性肾衰竭发生率更低,但脊髓缺血发生率更高。
- 两组长期生存无显著差异,腔内组随访期再干预增加。
核心结论
- 汇总14项研究显示,肾旁腹主动脉瘤腔内修复较开放手术降低30天死亡率、急性肾衰竭、肠缺血和住院时间,但增加脊髓缺血。
研究设计与样本
- 系统综述与荟萃分析,检索OVID Medline和Embase 2000年1月至2018年12月文献,纳入14项研究共5121例患者(腔内1506例、开放3615例),采用随机效应模型合并数据。
主要发现
- 腔内修复组30天死亡率显著降低(OR 0.50,95%CI 0.34-0.74,P<.001,I2=0%),仅纳入开窗EVAR时仍显著(OR 0.55,95%CI 0.36-0.85,P=.007,I2=0%)。
- 腔内修复组急性肾衰竭发生率显著降低(OR 0.50,95%CI 0.28-0.89,P=.02,I2=67%),脊髓缺血发生率显著升高(OR 3.14,95%CI 1.08-9.09,P=.03,I2=0%)。
- 腔内修复组住院时间显著缩短(平均差-5.99天,95%CI -7.42至-4.57天,P<.00001,I2=78%)。
- 腔内修复组患者年龄更大(平均差3.42,95%CI 2.54-4.3,P<.001,I2=56%),男性比例更高(OR 1.33,95%CI 1.02-1.73,P=.04,I2=33%)。
- 报告长期生存的9项研究中8项未发现组间显著差异,1项显示开放组长期生存更优;腔内组随访期再干预增加。
关键数值与推荐
- 30天死亡率OR 0.50(95%CI 0.34-0.74,P<.001);仅开窗EVAR的OR 0.55(95%CI 0.36-0.85,P=.007)。
- 急性肾衰竭OR 0.50(95%CI 0.28-0.89,P=.02);脊髓缺血OR 3.14(95%CI 1.08-9.09,P=.03)。
- 住院时间平均差-5.99天(95%CI -7.42至-4.57天,P<.00001)。
临床怎么用
- 对于肾旁腹主动脉瘤,腔内修复可作为降低围手术期死亡率和急性肾衰竭的选项,但需警惕脊髓缺血风险并加强监测。
- 腔内修复可缩短住院时间,但随访期再干预较多,需重视长期随访。
- 选择术式时应结合患者年龄、合并症及解剖条件个体化决策。
局限性
- 纳入研究存在偏倚风险,长期生存数据未合并分析,需进一步长期研究验证差异是否持续。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objectives of the present study were to summarize and pool the available data from studies that had directly compared endovascular and open repair of juxtarenal aortic aneurysms. METHODS: OVID Medline and Embase were searched for studies from January 2000 to December 2018 that had compared endovascular vs open repair of juxtarenal aortic aneurysms. Studies that had included patients with pararenal and suprarenal aneurysms were also included. The endovascular interventions included short-neck standard endovascular aneurysm repair (EVAR), parallel grafts, and fenestrated/branched EVAR. The primary outcomes were 30-day mortality, perioperative reinterventions, acute renal failure, permanent dialysis, stroke, and spinal cord ischemia. The secondary outcomes were myocardial infarction, bowel and limb ischemia, length of stay, and long-term survival. The data were pooled, and a meta-analysis using a random effects model was performed. RESULTS: A total of 20 studies met the inclusion criteria. Of the 20 studies, five had contained duplicated data and one had included only 2-year follow-up data. Therefore, 14 studies with 5121 patients (1506 endovascular, 3615 open) were included for analysis. The patients undergoing endovascular repair were older (mean difference, 3.42; 95% confidence interval [CI], 2.54-4.3; P < .001; I2 = 56%), more likely to be men (odds ratio [OR], 1.33; 95% CI, 1.02-1.73; P = .04; I2 = 33%), and more likely to have diabetes (OR, 1.24; 95% CI, 1.04-1.50; P = .02; I2 = 0%), coronary artery disease (OR, 1.64; 95% CI, 1.03-2.62; P = .04; I2 = 75%), and chronic kidney disease (OR, 1.52; 95% CI, 1.07-2.15; P = .02; I2 = 50%). Endovascular repair was associated with significantly decreased 30-day mortality (OR, 0.50; 95% CI, 0.34-0.74; P < .001; I2 = 0%). This remained significant when including only fenestrated EVAR (OR, 0.55; 95% CI, 0.36-0.85; P = .007; I2 = 0%). Endovascular repair also resulted in a significantly decreased incidence of acute renal failure (OR, 0.50; 95% CI, 0.28-0.89; P = .02; I2 = 67%), an increased incidence of spinal cord ischemia (OR, 3.14; 95% CI, 1.08-9.09; P = .03; I2 = 0%), a decreased incidence of bowel ischemia (OR, 0.50; 95% CI, 0.24-1.05; P = .07; I2 = 7%), and decreased length of stay (mean difference, -5.99 days; 95% CI, -7.42 to -4.57 days; P < .00001; I2 = 78%). No significant differences were found for the other outcomes. Of the nine studies that had reported long-term survival (1-7 years of follow-up), eight had found no significant differences between groups (data not pooled) and one study had found improved long-term survival in the open repair group. Reinterventions during follow-up were increased in the endovascular group. CONCLUSIONS: Pooling data from 14 studies, we found endovascular repair was associated with lower 30-day mortality, acute renal failure, bowel ischemia, and length of stay but with increased spinal cord ischemia. These data were limited by the risk of bias of the included studies. Further long-term studies are needed to determine whether these differences persist during long-term follow-up.
引用
- Doonan RJ, Girsowicz E, Dubois L, et al. A systematic review and meta-analysis of endovascular juxtarenal aortic aneurysm repair demonstrates lower perioperative mortality compared with open repair. J Vasc Surg. 2019. PMID: 31327612. doi:10.1016/j.jvs.2019.04.464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。